Company: Daiichi Sankyo
Job title: Senior Vice President, Global Head, Oncology Development
Dr. Gilles Gallant is an oncology expert with broad biotechnology and pharmaceutical experience in strategic cancer drug development, evaluation, and innovations. Gillesjoined DaiichiSankyo,Inc. (Basking Ridge, New Jersey) in 2017 as Vice President, Global Team Leader, Oncology Research &Development. Daiichi SankyoCancer Enterprise’s mission is to leverage world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. He is now leading the global development of all Daiichi Sankyo oncology assets.
Prior to joining Daiichi Sankyo, Dr. Gallantdesigned and directed global registrational and non-registrational clinical trials of Bristol-Myers Squibb oncology pipeline resulting in the worldwide approval of three indications (lung cancer (NSCLC), breast cancer and ovarian cancer) for the blockbuster Taxol®. As VP of Clinical Oncology, he has led the development strategy and clinical implementation for all oncology and hematology assets at Human Genome Sciences (HGSI) and later at BioMarin Pharmaceutical(BMRN)leading to the approval of Talzenna™. Gilles has guided oncology, hematology and immunology in-and out-licensing activities leading the in-licensing of two oncology drug candidates, the GlaxoSmithKline acquisition of HGS and the acquisition of talazoparib by Medivation.
Dr. Gallant received his doctorate in medicinal chemistry and bachelor’s degree in pharmacy from the Université de Montréal in Montréal (Québec) Canada. He is an emeritus graduate ofCollège André-Grasset in Montréal (Québec) Canada. He has recently been namedFellowofthe Ordre des Pharmaciens du Québec(FOPQ)forhis impressive international career in oncology research and for the impact he has had on the life of thousands of patients by developing new oncology drugs. He has co-authored numerous scientific abstracts and peer-reviewed publications in the oncology research field, and is an active member of the Ordre des Pharmaciens du Québec (OPQ), the American Chemical Society(ACS), the American Association for Cancer Research (AACR), the American Society of Clinical Oncology(ASCO), the European Society for Medical Oncology(ESMO), the American Society of Hematology(ASH),the International Association for the Study of Lung Cancer (IASLC), and the Society of Nuclear Medicine(SNMMI).
The Development & Approval of Enhertu in Patients with Unresectable or Metastatic HER2-positive Breast Cancer 9:10 am
• Outlining the pre-clinical profile and mechanism of action of Enhertu ([Fam-] trastuzumab deruxtecan, DS-8201a, T-DXd) • Reviewing clinical development leading to the approval of Enhertu • Understanding the current development status of EnhertuRead more
day: Day One